Current Updates in Gene Therapy for Multiple Sclerosis
Date
2023-05-16
Authors
Hossam Tharwat Ali
Haya Mohamed
Yara Ashour
Idris Sula
Ahmed Elrefaey
Mennatullah Mohamed Eltaras
Mostafa Meshref
Journal Title
Journal ISSN
Volume Title
Publisher
Al-Quds University - Deanship of Scientific Research
Abstract
Background: Multiple sclerosis (MS) is the most common demyelinating disease affecting predominantly young adults. The underlying pathogenesis isn’t fully understood although autoimmune attacks against proteins in the CNS is the most accepted theory. Oligodendrocytes seem to be the most involved resulting in demyelinated axons. Currently, the management of MS focuses on relieving symptoms during acute attacks and preventing disease progression using disease-odifying agents such as interferon-beta, dimethyl fumarate, natalizumab, and fingolimod. Studies have proven long-term improvement on these drugs. However, possible side effects and curatively inducing or improving the repair process are major challenges.